Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;18(5):e13294.
doi: 10.1111/irv.13294.

Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Clara Mazagatos  1   2 , Jacobo Mendioroz  3 , Mercedes Belén Rumayor  4 , Virtudes Gallardo García  5 , Virginia Álvarez Río  6 , Ana Delia Cebollada Gracia  7 , Noa Batalla Rebollo  8 , María Isabel Barranco Boada  9 , Olaia Pérez-Martínez  10 , Ana Sofía Lameiras Azevedo  11 , Nieves López González-Coviella  12 , Daniel Castrillejo  13 , Ana Fernández Ibáñez  14 , Jaume Giménez Duran  15   16 , Cristina Ramírez Córcoles  17 , Violeta Ramos Marín  18 , Amparo Larrauri  1   2 , Susana Monge  1   19 ; SARI Sentinel Surveillance RSV Study Group
Collaborators, Affiliations

Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain

Clara Mazagatos et al. Influenza Other Respir Viruses. 2024 May.

Erratum in

Abstract

Background: Data from the sentinel surveillance system of severe acute respiratory infections in Spain were used to estimate the impact of administration of nirsevimab to children born from 1 April 2023 onwards.

Methods: Estimated RSV hospitalisations in < 1-year-olds during weeks 40, 2023, to 8, 2024, were compared to the number that would be expected after accounting for the background change in RSV circulation in the 2023/24 season, compared to 2022/23.

Results: We estimated 9364-9875 RSV hospitalisations less than expected, corresponding to a 74%-75% reduction.

Keywords: SARI; burden; impact; respiratory infections; respiratory syncitial virus; surveillance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Weekly respiratory syncytial virus (RSV) proxy hospitalisation rates, by age group and respiratory season (from week 40, to week 39 of the next year), sentinel SARI surveillance system in Spain. The proxy is obtained by multiplying the Severe Acute Respiratory Infection (SARI) syndromic hospitalisation rates by the proportion of laboratory tests positive for RSV among those with SARI and systematically tested. Stratification for groups < 1 year or 1–4 years is only available for season 2022/23 onwards.
FIGURE 2
FIGURE 2
Estimated number of observed respiratory syncytial virus (RSV) hospitalisations in < 1‐year‐olds in Spain, weeks 40/2023–8/2024. Expected cases are obtained by applying to the observed cases from the equivalent weeks in 2022/23 a scaling factor (see Table 1) in 1‐ to 4‐year‐olds (2023/24 expected [Model A]) or 1‐ to 110‐year‐olds (2023/24 expected [Model B]). The RSV proxy hospitalisation rates each week are applied to the population size by age group and autonomous community; data are aggregated across autonomous communities for the number of weekly cases in Spain, referred to as observed.
See this image and copyright information in PMC

References

    1. Wildenbeest J. G., Billard M. N., Zuurbier R. P., et al., “The Burden of Respiratory Syncytial Virus in Healthy Term‐Born Infants in Europe: A Prospective Birth Cohort Study,” The Lancet Respiratory Medicine 11, no. 4 (2023): 341–353, 10.1016/S2213-2600(22)00414-3. - DOI - PMC - PubMed
    1. “Beyfortus|European Medicines Agency,” [Internet] Accessed December 23, 2023, https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus.
    1. Muller W. J., Madhi S. A., Seoane Nuñez B., et al., “Nirsevimab for Prevention of RSV in Term and Late‐Preterm Infants,” The New England Journal of Medicine 388, no. 16 (2023): 1533–1534, 10.1056/NEJMc2214773. - DOI - PubMed
    1. Martinón‐Torres F., Mirás‐Carballal S., and Durán‐Parrondo C., “Early Lessons From the Implementation of Universal Respiratory Syncytial Virus Prophylaxis in Infants With Long‐Acting Monoclonal Antibodies, Galicia, Spain, September and October 2023,” Euro Surveillance 28, no. 49 (2023): 1–4, 10.2807/1560-7917.ES.2023.28.49.2300606. - DOI - PMC - PubMed
    1. Ponencia de Programa y Registro de Vacunaciones , “Comisión de Salud Pública Del Consejo Interterritorial Del Sistema Nacional de Salud. Recomendaciones de Utilización de Nirsevimab Frente a Virus Respiratorio Sincitial Para La Temporada 2023–2024 [Recomendations for the Use of Nirsevimab against the Respiratory Syncytial Virus for the 2023–2024 Season in Spain],” Madrid, July 2023, https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTr....

Publication types

Substances